These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 34331595)

  • 1. Submicron particle docetaxel intratumoral injection in combination with anti-mCTLA-4 into 4T1-Luc orthotopic implants reduces primary tumor and metastatic pulmonary lesions.
    Maulhardt H; Marin A; Hesseltine H; diZerega G
    Med Oncol; 2021 Jul; 38(9):106. PubMed ID: 34331595
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intratumoral submicron particle docetaxel inhibits syngeneic Renca renal cancer growth and increases CD4+, CD8+, and Treg levels in peripheral blood.
    Maulhardt HA; Marin AM; diZerega GS
    Invest New Drugs; 2020 Oct; 38(5):1618-1626. PubMed ID: 32198648
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting myeloid-derived suppressor cells in combination with primary mammary tumor resection reduces metastatic growth in the lungs.
    Bosiljcic M; Cederberg RA; Hamilton MJ; LePard NE; Harbourne BT; Collier JL; Halvorsen EC; Shi R; Franks SE; Kim AY; Banáth JP; Hamer M; Rossi FM; Bennewith KL
    Breast Cancer Res; 2019 Sep; 21(1):103. PubMed ID: 31488209
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential combination immunotherapy requirements for inflamed (warm) tumors versus T cell excluded (cool) tumors: engage, expand, enable, and evolve.
    Fabian KP; Padget MR; Fujii R; Schlom J; Hodge JW
    J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33602696
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intratumoral Injection of Large Surface Area Microparticle Taxanes in Carcinomas Increases Immune Effector Cell Concentrations, Checkpoint Expression, and Synergy with Checkpoint Inhibitors: A Review of Preclinical and Clinical Studies.
    diZerega GS; Maulhardt HA; Verco SJ; Marin AM; Baltezor MJ; Mauro SA; Iacobucci MA
    Oncol Ther; 2024 Mar; 12(1):31-55. PubMed ID: 38289576
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Releasing the brakes of tumor immunity with anti-PD-L1 and pushing its accelerator with L19-IL2 cures poorly immunogenic tumors when combined with radiotherapy.
    Olivo Pimentel V; Marcus D; van der Wiel AM; Lieuwes NG; Biemans R; Lieverse RI; Neri D; Theys J; Yaromina A; Dubois LJ; Lambin P
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33688020
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhancement of antitumor immunity by combining anti-cytotoxic T lymphocyte antigen-4 antibodies and cryotreated tumor lysate-pulsed dendritic cells in murine osteosarcoma.
    Kawano M; Itonaga I; Iwasaki T; Tsumura H
    Oncol Rep; 2013 Mar; 29(3):1001-6. PubMed ID: 23291864
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic depletion of CCR8
    Van Damme H; Dombrecht B; Kiss M; Roose H; Allen E; Van Overmeire E; Kancheva D; Martens L; Murgaski A; Bardet PMR; Blancke G; Jans M; Bolli E; Martins MS; Elkrim Y; Dooley J; Boon L; Schwarze JK; Tacke F; Movahedi K; Vandamme N; Neyns B; Ocak S; Scheyltjens I; Vereecke L; Nana FA; Merchiers P; Laoui D; Van Ginderachter JA
    J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33589525
    [TBL] [Abstract][Full Text] [Related]  

  • 9. l-arginine and docetaxel synergistically enhance anti-tumor immunity by modifying the immune status of tumor-bearing mice.
    Cao Y; Wang Q; Du Y; Liu F; Zhang Y; Feng Y; Jin F
    Int Immunopharmacol; 2016 Jun; 35():7-14. PubMed ID: 27003114
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intratumoral delivery of encapsulated IL-12, IL-18 and TNF-alpha in a model of metastatic breast cancer.
    Sabel MS; Su G; Griffith KA; Chang AE
    Breast Cancer Res Treat; 2010 Jul; 122(2):325-36. PubMed ID: 19802695
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pingyangmycin enhances the antitumor efficacy of anti-PD-1 therapy associated with tumor-infiltrating CD8
    Shan CK; Du YB; Zhai XT; Wang YX; Li Y; Gong JH; Ge ZJ; Liu XJ; Zhen YS
    Cancer Chemother Pharmacol; 2021 Mar; 87(3):425-436. PubMed ID: 33388950
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Poxvirus-based active immunotherapy synergizes with CTLA-4 blockade to increase survival in a murine tumor model by improving the magnitude and quality of cytotoxic T cells.
    Foy SP; Mandl SJ; dela Cruz T; Cote JJ; Gordon EJ; Trent E; Delcayre A; Breitmeyer J; Franzusoff A; Rountree RB
    Cancer Immunol Immunother; 2016 May; 65(5):537-49. PubMed ID: 26961085
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extracellular HMGB1 blockade inhibits tumor growth through profoundly remodeling immune microenvironment and enhances checkpoint inhibitor-based immunotherapy.
    Hubert P; Roncarati P; Demoulin S; Pilard C; Ancion M; Reynders C; Lerho T; Bruyere D; Lebeau A; Radermecker C; Meunier M; Nokin MJ; Hendrick E; Peulen O; Delvenne P; Herfs M
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33712445
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IL2/Anti-IL2 Complex Combined with CTLA-4, But Not PD-1, Blockade Rescues Antitumor NK Cell Function by Regulatory T-cell Modulation.
    Caudana P; Núñez NG; De La Rochere P; Pinto A; Denizeau J; Alonso R; Niborski LL; Lantz O; Sedlik C; Piaggio E
    Cancer Immunol Res; 2019 Mar; 7(3):443-457. PubMed ID: 30651291
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Invariant natural killer T cells regulate breast cancer response to radiation and CTLA-4 blockade.
    Pilones KA; Kawashima N; Yang AM; Babb JS; Formenti SC; Demaria S
    Clin Cancer Res; 2009 Jan; 15(2):597-606. PubMed ID: 19147765
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recombinant virus-like particles presenting IL-33 successfully modify the tumor microenvironment and facilitate antitumor immunity in a model of breast cancer.
    Feng X; Liu H; Chu X; Sun P; Huang W; Liu C; Yang X; Sun W; Bai H; Ma Y
    Acta Biomater; 2019 Dec; 100():316-325. PubMed ID: 31542504
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduced infiltration of regulatory T cells in tumours from mice fed daily with gamma-tocotrienol supplementation.
    Subramaniam S; Anandha Rao JS; Ramdas P; Ng MH; Kannan Kutty M; Selvaduray KR; Radhakrishnan AK
    Clin Exp Immunol; 2021 Nov; 206(2):161-172. PubMed ID: 34331768
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aptamer targeted therapy potentiates immune checkpoint blockade in triple-negative breast cancer.
    Camorani S; Passariello M; Agnello L; Esposito S; Collina F; Cantile M; Di Bonito M; Ulasov IV; Fedele M; Zannetti A; De Lorenzo C; Cerchia L
    J Exp Clin Cancer Res; 2020 Sep; 39(1):180. PubMed ID: 32892748
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Docetaxel-loaded solid lipid nanoparticles prevent tumor growth and lung metastasis of 4T1 murine mammary carcinoma cells.
    da Rocha MCO; da Silva PB; Radicchi MA; Andrade BYG; de Oliveira JV; Venus T; Merker C; Estrela-Lopis I; Longo JPF; Báo SN
    J Nanobiotechnology; 2020 Mar; 18(1):43. PubMed ID: 32164731
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mammary tissue microenvironment determines T cell-dependent breast cancer-associated inflammation.
    Takahashi K; Nagai N; Ogura K; Tsuneyama K; Saiki I; Irimura T; Hayakawa Y
    Cancer Sci; 2015 Jul; 106(7):867-74. PubMed ID: 25940224
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.